The migration of human monocytes across unactivated and activated human umbilical vein endothelium (HUVE) in response to chemotactic factors was studied, and the adhesion molecules involved were characterized. Migration of blood monocytes or U937 cell line-derived monocytes across unactivated HUVE induced by C5a, was partially inhibited (by 75%) by mAbs (R15.7 or 60.3) to CD18 of the CD11/CD18 complex on the monocyte. However, when the HUVE was pretreated for 5 h with IL-la (0.1 ng/ml), TNF-a (100 U/ml), or LPS (1 ng/ml), migration induced by C5a was no longer inhibited; i.e., migration became CD18 independent. The monocyte CD18-independent migration was completely blocked by mAbs against a4 or 01 integrin chains of VLA4. This migration was also partially inhibited by mAbs against vascular cell adhesion molecule-i (VCAM-1), a major counter-receptor on HUVE for VLA4, but not by mAbs to E-selectin or intercellular adhesion molecule-i. The significant CD18-independent migration across "unactivated" HUVE was also inhibited by mAbs against a4 or #I chains of VLA4, although mAbs against VCAM-1 did not inhibit under these conditions. Finally, considerable VLA4-dependent transendothelial migration to C5a was also observed with monocytes from a patient with CD18 deficiency (leukocyte adhesion deficiency). These results suggest that (a) there is a major CD18-independent component in monocyte chemotactic factor-dependent migration across activated and unactivated endothelium; (b) that VLA4 integrin on the monocyte has a major role in this migration; and (c) that VCAM-1 on activated endothelium functions as a counter-receptor in this process, but other ligands for VLA4, especially on unactivated endothelium, may also be involved. (J. Clin. Invest. 1993. 92:2768-2777
Introduction
The movement of monocytes and polymorphonuclear leukocytes (PMNL)' from blood into tissues is a characteristic fea-ture of inflammation. At the present time, the mechanisms of monocyte infiltration into inflammatory sites are not fully understood. However, involvement of chemotactic factors produced in the inflamed tissue (1-3) appear to be important in leukocyte emigration from the blood across vascular endothelium. Chemotactic factor-dependent migration involves binding ofthe factor to specific membrane receptors on PMNL and monocytes and intracellular signal transduction (4) . Chemotactic factor-induced migration of PMNLs and monocytes does not require other cell types (1, 2, 5) but is dependent on the l2 integrin (CDl 1/CD 18) leukocyte surface molecules because mAbs to these adhesion molecules markedly inhibit migration (6, 7) . Furthermore, in patients whose leukocytes are congenitally deficient in the CDl 1/CD 1 8 proteins, their PMNLs fail to migrate across endothelial monolayers in response to chemoattractants (6, 8, 9) . However, the role of CDl 1/CD 1 8 proteins in chemotactic factor-dependent migration of monocytes is only partial because mAbs against the common l2 subunit (CD 18) only partially (< 75%) inhibit migration (10, 11) , suggesting that a CDl18-independent mechanism may also be involved in monocyte chemotactic factordependent migration.
Recently, leukocyte migration has been recognized as having an important endothelial cell dependent component. This mechanism involves the activation ofendothelial cells by cytokines such as IL-1, TNF-a, or the bacterial product endotoxin (LPS) (3) . In this process, endothelial cells undergo profound functional alterations and express adhesion molecules for leukocytes. These stimuli do not induce PMNL migration directly, but we and others have shown that IL-1, TNF-a, and LPS activate vascular endothelial cells in vitro to increase PMNL adhesion and transendothelial migration (3, 6, (12) (13) (14) . This process involves increased surface expression on the endothelial cell of the membrane glycoproteins E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule (VCAM-1) (3, 15, 16) . These molecules on the endothelium interact with sialyl Lewis X containing molecules, the CDl 1/CD 18 and the VLA-4 integrins (a43,), respectively, on leukocytes including monocytes (3, (17) (18) (19) (20) .
For PMNL migration, the interaction of CD 1 /CD 18 with ICAM-1 on activated endothelium appears essential (6, 13) . However, the adhesion/migration mechanisms involved in monocyte transendothelial migration is less clear. To date, most ofthe studies with monocytes have focused on their adhesion mechanisms (21) (22) (23) (24) or migration stimulated by chemotactic factors (1 1, 25-27) . There have been few studies of cytokine-activated endothelial cell-dependent migration. This is, in part, because it has been difficult to demonstrate this mechanism in vitro with monocytes because of a weaker migration response and a higher unstimulated background response than with PMNL (10, 28) . However, in vivo studies clearly show that monocyte infiltration and migration occur rapidly at tissue sites injected with endothelium-activating cytokines such as IL-I, TNF-a, or LPS (29) (30) (31) . One reason for such discrepancy could be that in vivo, both endothelial cell-dependent and monocyte chemotactic factor-dependent mechanisms may be simultaneously operative, since IL-1, TNF-a, and LPS are now known to induce the synthesis by connective tissue cells of chemotactic factors for leukocytes, including monocytes (32, 33) . Furthermore, it is increasingly recognized that inflamed tissues and exudate fluids contain pathophysiologically relevant concentrations of monocyte chemotactic factors (e.g., C5a, leukotriene B4, and monocyte chemotactic protein-1 in conjunction with IL-1 and TNF (2, 32, 34, 35) . In such tissues, the local vascular endothelium expresses leukocyte adhesion molecules, suggesting activation by the latter cytokines (29, 36, 37) . Therefore, to model this complex in vivo situation, we investigated monocyte migration in vitro in response to chemotactic factors across both resting and IL-I-, TNF-a-, or LPS-activated HUVE. Under these migration conditions, we studied the monocyte and endothelium adhesion molecules required for monocyte migration. Our results indicate that chemotactic factors induce marked migration ofmonocytes across resting and activated endothelium. Furthermore, in the presence of an activated endothelium, the CD1 1/CD 18 complex is not required for migration, but rather, the VLA-4 integrin can function as an alternative mechanism for the migration of monocytes.
Methods
Monoclonal antibodies. A number of function-blocking mAbs were generously provided for these studies. These included mAbs 60.3 (IgG2, from Dr. J. M. Harlan, University of Washington, Seattle, WA) (38) Monocyte isolation from normal donors and a patient with CD18 deficiency. Sterile plasticware and pyrogen-free water (Travenol, Malton, Ontario, Canada) and solutions were used throughout. Venous blood from healthy human volunteers and from a patient with leukocyte adhesion deficiency (LAD) was collected into EDTA (0.1 %) plus acid citrate dextrose (0.8 ml/10 ml of blood, acid citrate dextrose formula A; Travenol) anticoagulant. The LAD patient has previously been reported (47) . He has severe CD18 deficiency with < 4% of normal expression of the CD 11/CD 18 molecular complex on leukocytes. The blood sample from this boy was collected by Dr. Zave Chad (H6pital Ste. Justine, Montreal, PQ), along with a sample from a control, and couriered overnight to our laboratory for study. The red cells in the blood samples were separated by sedimentation with 6% dextran saline solution (Travenol) (1 part to 5 of blood) and the leukocyte-rich plasma was harvested. The leukocytes were sedimented (150 g X 10 min at 220C), the pellet was resuspended in Ca", Mg"+-free Tyrode's solution with 5% autologous platelet-poor plasma, and labeled with 5"Cr sodium chromate (25 utCi/ml) (Amersham Corp., Oakville, Ontario, Canada) by incubation for 30 min at 370C. During this incubation, the osmolarity of the medium was gradually increased in three steps from 290 to 360 mosmol by addition of 9% NaCl, as previously described by Boyum (48) and Recalde (49) . This improved the monocyte purity and did not affect cell viability or function as reported previously (48, 49) . After the incubation period, labeled leukocytes were washed once with Ca", Mg"+-free Tyrode's solution (360 mosmol), 5% PPP, and resuspended in hyperosmotic (360 mosmol) Ca", Mg"+-free Tyrode's solution containing 0.2% EDTA and 10% plateletpoor plasma-Percoll (Pharmacia Fine Chemicals, Dorval, PQ) to achieve 56% Percoll concentration (based on 100% = isotonic Percoll). Six different Percoll cushions of 2.5 ml each were layered in a 15-ml conical polypropylene tube with 73% Percoll at the bottom followed by 62%, 56% (containing the labeled leukocytes), 50%, 46%, and 40%. Density gradient centrifugation was at 400 g (25 min at 220C) in a swinging bucket rotor. Six bands were resolved, harvested, and washed twice with isotonic Ca", Mg++-free Tyrode's solution-0. 1% HSA (LPS free). The purest monocyte fraction was recovered at the 46-40% Percoll interphase yielding 3-4 X 106 monocytes from 40 ml of starting blood with > 90% purity, > 95% viability by neutral red staining and trypan blue exclusion, and minimal platelet contamination. Platelets were found to band above the 40% Percoll cushion. Monocytes were identified by neutral red and nonspecific esterase staining (50) (52) , and cultured on filters as previously described by us (12 Gibco Laboratories). The HUVE were detached using 0.025% trypsin/ 0.01% Versene (MA Bioproducts, Walkerville, MD) and cultured on PVP-free polycarbonate filters bearing 51gm pores in 65-mm di culture plate inserts (Transwell 3415; Costar Corp., Cambridge, MA). The filters were first prepared by coating with 0.01% gelatin (37°C, 18 h) followed by application of 3 ,g in 50 Ml water of human fibronectin (Collaborative Research) at 37°C for 2 h. Fibronectin was then replaced by HUVE (2 X 104 cells) from the first or second passage, added above the filter in 0.1 ml growth medium, and 0.6 ml growth medium was added to the lower compartment beneath the filter. The HUVE formed a tight permeability barrier in 5-6 d, and were evaluated for confluence before use by '25I-HSA diffusion as previously described (12) .
Monocyte and U93 7 cell transendothelial migration. For migration assays, HUVE monolayers on the filters and the lower compartment beneath the filters were washed with RPMI 1640 and stimulated for 5 h by addition ofIL-la, TNF-a, or LPS to the lower compartment in fresh RPMI 1640 with 10% FCS. When IFN-T was used as stimulus, the cytokine was added to the lower compartment 5 or 20 h before the migration assay. After incubation with cytokines, the upper and lower surfaces of the HUVE filter units were washed with RPMI 1640, and then they were transferred to a new, clean well (lower compartment). To this well, 0.6 ml of RPMI-1640, 10 mM Hepes, 0.5% HSA was added containing the chemotactic stimulus (C5a or FNLP; Sigma Chemical Co.). Before immersion of the HUVE filter unit, 0.1 ml of medium containing 7 x 104 5'Cr monocytes or 105 5"Cr U937 were added above the HUVE. After incubation (usually 90 min), migration was stopped by washing of the upper compartment twice with 0.1 ml RPMI 1640 to remove nonadherent monocytes or U937. The undersurface of the filter was then vigorously rinsed with 2 ml of ice-cold PBS/0.2% EDTA solution and collected into the lower compartment. The HUVE filter unit (upper compartment) was then placed into 0.7 ml of 0.5 M NaOH to allow dissolution of adhered monocytes. The cells that migrated into the lower compartment or were detached from the undersurface of the filters by the cold PBS/EDTA were lysed by addition of 0.5% Triton X-100. The NaOH solution bathing the filters (adherent cells) and the contents of the lower chamber (migrated cells) were analyzed for 5"Cr and results are expressed as the percentage ofthe total 5"Cr-monocytes or U937 added above the HUVE, which were recovered in each fraction. All the stimulation conditions were performed with triplicate replicates.
Monoclonal antibody treatments. In some experiments, 5Cr-monocytes or 5"Cr-U937 were treated for 20 min at room temperature with the mAbs indicated at saturating concentrations Mg/ml) as determined by immunofluorescence flow cytometry, and then tested for migration in the presence of the antibody. In some experiments, the HUVE was treated for 40 
Results
Chemotactic factor-dependent monocyte migration. The optimal conditions for monocyte migration across HUVE monolayers was determined by performing dose response and time course experiments with the chemotactic factor, C5a . Fig. 1 a shows that all C5a concentrations tested significantly increased monocyte migration above control levels with 5 X 10-10 M inducing the maximal monocyte response. The transendothelial migration of monocytes in response to C5a as a function of time is shown in Fig. 1 Endothelial cell dependent IL-ia-induced monocyte migration. In the case of PMNL, activation ofthe HUVE by IL-I or TNF-a induces strong PMNL adhesion and marked transendothelial migration (25-35% of added PMNL) in this assay system as shown by us previously (12) . As shown in Fig. 2 a, IL-1a stimulation of the HUVE caused only a small amount (6.4%) of monocyte transendothelial migration but this was significantly greater than across unstimulated HUVE. This was associated with a more marked increase in monocyte adhesion (Fig. 2 b) . Neither an increase in the IL-la concentration in the duration of stimulation with IL-1 a < 24 h or in the migration time enhanced the IL-1-induced monocyte migration (not shown). A small increase in monocyte migration and more marked adhesion was observed also when TNF-a or LPS were used to activate the HUVE as shown in Fig. 2 . In contrast, IFN-y stimulation of the HUVE had no effect on monocyte migration or adhesion.
Requirementfor CD18 in chemotacticfactor-and endothelium-dependent monocyte migration. We next examined the role of CD1 1/CD 1 8 on monocytes in transendothelial migration. Fig. 3 shows that mAbs against the common CD18 8#2 partially inhibited (i.e., by 70%) C5a-induced monocyte transendothelial migration. It is important to point out that these mAbs to CD18 inhibited PMNL transendothelial migration to C5a in the same assay system by > 90% in agreement with published reports (6, 7) (data not shown). These results suggest the presence of a CD18-independent mechanism involved in monocyte chemotactic factor-dependent migration. The shaded bars in Fig. 3 show that the same mAbs to CD18 did not inhibit monocyte migration induced by C5a through an IL-1-activated endothelium. This lack of inhibition was not dependent on the chemotactic factor tested, since migration induced by FNLP across IL-la-activated HUVE was also unaffected by mAbs to CD18 (FNLP 3 X I0O' M + IL-la-activated HUVE = 20.2±1.4%; FNLP + IL-lcaactivated HUVE + mAb to CD 18 = 21.1±0.2% migrated). Fig.  4 shows that TNF-a and LPS activation of the HUVE (5 h pretreatment) also resulted in monocyte transendothelial migration to C5a, which was CD18 independent, since the mAbs to CD18 did not inhibit this migration. In contrast, IFN-r treatment (5 or 20 h) did not modify the inhibition observed with mAbs to CD18, suggesting that IFN-r is not able to upregulate on the HUVE, the mechanisms or adhesion molecules involved in CD 18-independent monocyte migration. It should be pointed out that the concentration (200 U/ml) and the lot of IFN--y used in these experiments was shown by us recently to upregulate ICAM-1 and potentiate LPS-induced PMNL transendothelial migration (53) .
To determine whether the CDl 8-independent monocyte migration might have been caused by the isolation procedure used or whether it might have selected for a subpopulation of monocytes, we also examined the migration of U937 cells, which is a monocyte-like cell line. After treatment ofthe U937 cells with dibutyryl cyclic AMP for 48-72 h, they acquired the capacity to migrate in response to C5a, as described previously by Gavison et al. (51) . Fig. 5 shows that mAbs against CD18 partially inhibited the migration ofU937 cells to zymosan-activated plasma (ZAP), the active component ofwhich is C5a des Arg (54 Molecules involved in CD18-independent monocyte migration across IL-l a-activated endothelium. We investigated the mechanisms that may contribute to CD I 8-independent migration by using mAbs directed against adhesion molecules on the surface of monocytes and on endothelial cells. The participation ofE-selectin, ICAM-1, and VCAM-l was assessed by incubating IL-la-treated HUVE with specific blocking mAbs against E-selectin, ICAM-1, or VCAM-1, and quantitating the C5a-induced migration of monocytes, which were treated with mAb to CD 18. All of the mAbs were present during the assay. Fig. 6 a shows that mAb 2G7 (or 4B9, not shown) against VCAM-I inhibited the CD I 8-independent migration induced by C5a across IL-a-activated HUVE, suggesting that VCAM-1 on the HUVE is involved in CDl 8-independent migration. This inhibition by 2G7 was not potentiated by mAbs 5D10 or 84H10 (not shown) against ICAM-1 and BB 11 against E-selectin in combination with 2G7. The control mAb W6/32 against an HLA-class I framework epitope had no effect on migration.
To determine the molecules involved on the surface of the monocyte in this CD 18-independent migration, we preincubated the monocytes with mAb to CD1 8 plus blocking mAb HP1/2 to the a4 integrin chain of VLA-4 or mAbl 3 to j3, integrin, or mAb DREG200 to L-selectin or mAb CSLEX to the sialyl LewX carbohydrate. Fig. 6 b shows that ofthese, only the mAb against a4 (HP 1/2) or against #, integrin (mAb l 3) inhibited the CD1 8-independent migration. It is important to point out that the inhibition is almost complete by mAb HP1/2, as well as by mAbl 3, suggesting that VLA-4 on the monocyte is a major CD18-independent migration mechanism.
Molecules involved in CD18-independent migration across unactivated endothelium. The adhesion molecules involved in CD 18 studied by using blocking mAbs against molecules on the surface ofthe monocyte and endothelial cell as above. As shown in Fig. 7 a, the same mAbs used in Fig. 6 against E-selectin (BB I 1), ICAM-I (5D10), or VCAM-I (2G7) did not inhibit significantly the remaining C5a-induced migration of monocytes after treatment with mAb to CD 1 8 (i.e., the CD1 8-independent component) across unactivated HUVE. This CD 8-independent migration was -30% of maximal as shown above in Fig. 3 (open bars). Even when these mAbs were used in combination, the migration on unactivated HUVE was not significantly inhibited. The participation of VLA-4 in CDl 8-independent migration on unactivated HUVE was confirmed by preincubating the cells with the blocking mAb HP 1/2, Abl3, DREG200, or CSLEX as also performed in Fig. 6 . Fig. 7 b shows that mAb against a4, i.e. HP 1/2 or against #I integrin (mAbl 3), inhibited the CD18-independent migration across unactivated HUVE, suggesting that VLA-4 is involved in CD18-independent migration across unactivated HUVE, as well as across IL-aactivated HUVE (Fig. 6 b) . the CD1 8-deficient monocytes was not inhibited by addition of mAb to CD18 (60.3) under any of the migration conditions tested (Table I) . Discussion Role of VLA-4 in CSa-induced monocyte migration across unactivated or IL-I a-activated HUVE. To more clearly determine the role of VLA-4 in C5a-induced monocyte migration through unactivated or IL-la-activated HUVE, labeled 5'Crmonocytes treated with mAb HP1/2 to a4 chain of VLA-4 or mAb 60.3 to CD1 8 were tested for migration. Fig. 8 a shows that HP 1/2 alone caused a slight but not statistically significant decrease in C5a-induced migration across unactivated HUVE. The mAb against CD1 8 caused a 70% inhibition. Both mAbs together blocked migration almost completely (> 90% inhibition). However, when the HUVE was activated by IL-la, neither mAb alone inhibited the C5a-induced migration. However, when used in combination, there was almost a total inhibition; i.e. to near unstimulated migration in the absence ofC5a.
Migration ofCD] I/CD18-deficient monocytes. We had the opportunity to perform one experiment with monocytes from a patient reported previously (47) to have congenital LAD with nearly complete CD1 8 deficiency (< 4% of normal). Table I shows that the LAD patient's monocytes were impaired in migration to CSa across unactivated HUVE, although they did show some response. However, migration to C5a increased markedly from 5.9% on unactivated HUVE to 19.5% when the HUVE was activated with IL-I a. Although this migration was less than the normal control used that same day, this could only be performed once because ofthe availability ofpatient blood. The migration ofthe LAD monocytes was completely blocked by mAb HP1/2 to a4 and nearly completely by mAbl 3 to (31 integrin, confirming that VLA-4 (a4 (31) is required for these CDl 1/CD1 8-deficient monocytes to migrate. The migration of Under most conditions examined in vitro and in vivo, the leukocyte CD 1I/CD 18 or (2 integrin complex is required for PMNL and monocyte migration. This is supported by the finding that mAb against the common (3 chain (CD 1 8) (3, 6, (12) (13) (14) . These cytokines also increase monocyte adhesion and migration, although the migration response across activated HUVE is much weaker than with PMNL (21) (22) (23) (24) 28) . This monocyte behavior in vitro contrasts with in vivo findings, which show a strong monocyte recruitment to sites injected with these agents (3, (29) (30) (31) . The weak in vitro monocyte migration across IL-1 or TNF-aactivated endothelium was considered by Hakkert et al. (28) to be related to the type of subendothelial matrix used for the HUVE. However, even with attempts by these authors to optimize this component, monocyte migration across IL-1-treated HUVE was much less than for PMNL (28) . In the system described here, we examined the effect ofdifferent types ofmatrix (data not shown), but observed no significant effect on the relatively low monocyte migration shown in Fig. 2 , across IL-1-activated HUVE.
Another factor we considered to be contributing to the monocyte migration observed in vivo is the generation of chemotactic factors since in sites of inflammation (e.g., synovial fluid and lung), these direct monocyte acting factors and endothelial activating cytokines such as IL-1 and TNF-a can be present simultaneously (2, 3, (32) (33) (34) (35) . Furthermore, the vascular endothelium in inflamed tissues has been found to be "activated" with expression of leukocyte adhesion molecules (29, 37) . Therefore, in this study, monocyte migration in response to chemotactic factors across unactivated and cytokine activated endothelium was investigated to simulate this in vivo situation. The migration induced by C5a was rapid and strong ( Fig. 1) , irrespective of whether or not the endothelium was activated (Figs. 3 and 8 ). This migration across unactivated HUVE was largely CD1 8 dependent, since three different mAbs against CD I 8-inhibited monocyte migration by 70-75% in response to C5a (Figs. 3 and 4) or FNLP (not shown). However, migration induced by these chemotactic factors across IL-1-, TNF-a-, or LPS-activated HUVE was completely CD 18 independent because these same mAbs failed to inhibit migration at all under these conditions (Figs. 3 and 4 and text) . The same results were obtained when the U937 cell line-derived monocyte-like cells were tested for migration under the same conditions (Fig. 5) . This suggests that the CDl 8-independent migration observed is not the result of the purification process used to obtain blood monocytes, but rather, a property of monocyte lineage cells.
It is well known that on IL-I-, TNF-a-, or LPS-pretreated endothelium adhesion molecules such as E-selectin, ICAM-1, and VCAM-1 are upregulated, increasing the adhesiveness for PMNLs and monocytes (3, 17, 18) . In this study, we show that the CD1 8-independent migration mechanism is enhanced by IL-la, TNF-a, or LPS pretreatment ofHUVE, but not by IFNr (Fig. 2) . This is of interest because IFN-T does not induce E-selectin or VCAM-l on HUVE, although it does enhance expression ofICAM-1 (3, 16, 17, 21) . This observation suggests ICAM-l upregulation is not sufficient to mediate CDI8-independent monocyte migration.
The role of E-selectin in monocyte and U937 cell binding has been previously studied. Although E-selectin appears to play a role in monocyte adhesion (21, 22, 24) , it is not required in the CD1 8-independent migration observed here, since the adhesion blocking mAb BB 11 against E-selectin (46) had no effect on migration alone (not shown) or in combination with mAbs against ICAM-1 (Fig. 6 a) . Also L-selectin, which appears to be important for monocyte adhesion under shear force conditions (23), was not required for the migration we observed (Fig. 6 b) . However, our results show that the treatment of the activated HUVE with mAbs 2G7 (or 4B9, not shown), which block VCAM-1-mediated adhesion to VLA-4 (16, 44), or the treatment of the monocytes with mAb HP 1/2 to a4, which blocks the adhesion function of VLA-4 (42), essentially abolished the CDl 8-independent monocyte migration to C5a across IL-l-activated HUVE (Fig. 6 b) . This finding, combined with the fact that mAbl 3, which reacts with fB integrin chain and blocks adhesion functions of 3, integrins (43) , was essentially as effective for inhibition as mAb HP1/2, strongly suggests that interaction between VCAM-1 on the HUVE and VLA-4 (a431) on the monocyte mediate CD18-independent migration across IL-l-activated HUVE. The importance of the 4 subunit, and specifically of the o4 cytoplasmic domain of VLA-4 for cell migration, has recently been elegantly shown using chimeric a2, a4, and a5 chains in transfected rhabdomyosarcoma cells (55) . These findings are in agreement with our recent observations, that mAb to another #I integrin a chain, namely to a5 (mAb 16) does not inhibit monocyte CDl 8-independent migration (data not shown).
It is important to point out that in the presence of mAb to CD1 8, mAbs HP 1/2 and Abl 3 were able to inhibit monocyte migration almost until basal levels across both unactivated and IL-1-activated HUVE, while mAbs 2G7 or 4B9 against VCAM-1 decreased only the IL-l-enhanced CDl 8-independent migration and the anti-VCAM-1 mAbs were less effective than the anti-a4 mAb (HP 1/2) (Fig. 6, 7) . These results do not appear to be caused by limiting amounts of mAbs because addition of four times higher concentrations of mAb to CD1 8 or to VCAM-I gave the same results (data not shown). There may be several reasons for the more potent inhibition by mAb to a4 or fl, than by mAbs to VCAM-1: (a) VLA-4 can bind not only to VCAM-1, but also to CS-I fragment of fibronectin, a ligand present also on unactivated HUVE and mAb HP 1/2 blocks VLA-4 binding to both (42, 56) ; (b) the mAbs used to block VCAM-l on the activated HUVE bind to domain 1 on VCAM-1, while VLA-4 binds to more than one domain (57-59); and (c) another molecule present on activated and unactivated HUVE may also serve as a ligand for VLA-4. Currently, we are studying the second possibility by using mAbs against different domains of VCAM-1 (kindly provided by Dr. R. Lobb). Preliminary results show that both domains 1 and 4 need to be blocked simultaneously to observe complete inhibition of CD18-independent monocyte migration. Thus, this suggests that VCAM-1 on the endothelium may be the only ligand for mediating the VLA-4-dependent migration observed here. Further studies are ongoing to confirm these results. The results with monocytes from a patient with LAD, congenitally deficient in CDl 1/CD 1 8 (homozygous) (< 4% of normal) (47) would appear to rule out the possibility that the mAbs to CD1 8 were not sufficient to block all CDl 1/CD 1 8-dependent migration, since the LAD monocytes also migrated well across IL-I-activated HUVE, and to a lesser extent, across unactivated HUVE in response to CSa (Table I ). These LAD monocytes also appeared to utilize VLA-4 as an alternative migration mechanism because mAb to a4-or fl,-inhibited migration, while mAbs to CD1 8 had no effect on the migration of these monocytes (Table I) .
On IL-l-activated HUVE, neither CDl l/CDl 8 nor VLA-4 alone appear to be required for migration to chemotactic factors such as C5a because blocking either of these integrins alone did not inhibit the migration response (Fig. 8 b) . Thus, one mechanism may substitute for the other on monocytes, and both mechanisms must be blocked to abolish monocyte migration across activated endothelium. In contrast, migration across unactivated endothelium in response to chemotactic factor is much more CDl 1/CD1 8 dependent (Fig. 8 a) , and VLA-4 functions as a less efficient alternative mechanism, perhaps because unactivated endothelium expresses fewer or lower affinity ligands for VLA-4 on the monocytes.
In addition to monocytes, lymphocytes, eosinophils, and basophils express VLA-4 (56). Neutrophils lack this integrin. The VLA-4 on basophils, eosinophils, and T lymphocytes has been shown by a number of studies to contribute to the adhesion ofthese leukocytes to cytokine-activated endothelium (58, 60, 61) . This adhesive function of VLA-4 involves, at least in part, VCAM-l on the endothelium. However, most of the in vitro studies of the mechanism involved in the migration of T lymphocytes or eosinophils across IL-1-activated endothelium have identified a predominant role for CDl 1/CD 18, with only a minor or insignificant contribution of VLA-4 or its ligand, VCAM-1, to the migration process (62, 63). This conclusion was also reached for T lymphocyte transendothelial migration in response to lymphocyte chemotactic factors (64) . However, our finding that VLA-4 in monocytes can play a major role, in addition to CDl 1/CD 18, in mediating cell migration is in agreement with a recent report that VLA-4 functions as a major mechanism by which eosinophils migrate across HUVE activated by IL-4 (but not IL-1) (65) . In addition to these in vitro observations, there are now an increasing number of in vivo studies that implicate VLA-4 as an important integrin in T lymphocyte migration in the rat to dermal inflammatory reactions (e.g., delayed type hypersensitivity, TNF-a) (66) , or to the central nervous system in experimental allergic encephalitis (67) . In this species, monocyte infiltration into the lung in IgA immune complex alveolitis (68) appears to also involve a VLA-4-mediated mechanism.
Thus, the in vitro observations reported here demonstrating a major role on monocytes for VLA-4, and of one of its major ligands, VCAM-1 in transendothelial migration, is in accord with the increasing evidence of an important role for VLA-4 in leukocyte migration in vivo. Further studies in vitro should allow analysis at the molecule level of the contribution to monocyte migration of ligands for VLA-4 in addition to VCAM-1, the role of VLA-4, CDlI/CD18, and its subtypes (LFA-1, MAC-1, and gpl 50/95) in migration during various monocyte and endothelial cell activation conditions, and potentially lead to developing strategies for regulating monocyte migration in pathological conditions.
